An interventional study of Ovarian tissue allo-transplantation in Ovarian Failure, Ovarian Insufficiency and Menopause Ovarian Failure, sponsored by University Hospitals Cleveland Medical Center. Not yet recruiting at 1 site in United States. Open to female participants aged 21 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by University Hospitals Cleveland Medical Center · Not applicable, Interventional, and Treatment
Premature ovarian failure, also known as primary ovarian insufficiency (POI), or premature menopause, affects 1-2% of women under 40. The diagnosis is typically made based on high levels of follicle stimulating hormone (FSH) and absent or irregular menstrual periods. It leads to infertility and menopause-like effects (hot flashes and thin bones) due to low estrogen levels. POI can result from various factors such as genetic conditions, autoimmune diseases, or previous medical treatments like chemotherapy.
Treatment of POI usually involves hormone replacement therapy and, if pregnancy is desired, assisted reproductive technologies such as in vitro fertilization (IVF) using an egg donor. However, IVF may not be an option for everyone due to personal, religious, ethical or financial reasons. Recent advances in medicine have identified ovarian tissue transplantation (OTT) as a potential solution. OTT involves transplanting either fresh or frozen ovarian tissue into the pelvic area, where it can begin functioning again. Studies in animals and humans have shown success in restoring hormonal function and even achieving pregnancies in some cases. Initial human trials of ovarian tissue transplants from another individual began with identical twins and have since expanded to include non-identical siblings with compatible tissue matches using immunosuppression. Success rates of OTT have been promising, with multiple live births reported between identical twins. Long-term studies indicate that transplanted tissue can remain functional for up to eight years. Ovarian tissue transplantation offers a promising avenue for women with POI to help restore fertility and hormonal function. Continued research and refinement of tissue techniques are essential to improve outcomes and expand access to this innovative treatment option.
This study will enroll 10 participants who will undergo ovarian tissue transplantation donated by a non-identical sister using an immunosuppression protocol at University Hospitals.
Inclusion Criteria (Donor):
Inclusion Criteria (Recipient):
Inclusion Criteria (Recipient Male Partner)
Exclusion Criteria (Donor) (to be verified by history and review of the medical chart by the study team)
Exclusion Criteria (Recipient)
Exclusion Criteria (Recipient Male Partner )
Any recipient that receives ovarian tissue transplantation
Procedure: Ovarian tissue allo-transplantation
Participants will receive donor ovarian tissue with immunosuppression
Time (days) from transplantation to resumption of menses as measured by patient report
Time frame: Up to 6 months
Number of live births as measured by medical record report/patient report
Time frame: Up to 3 years
Time (days) from transplantation to pregnancy as measured by medical record/patient report
Time frame: Up to 2 years
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospitals Cleveland Medical Center